{
    "clinical_study": {
        "@rank": "125994", 
        "arm_group": {
            "arm_group_label": "Definity VCEUS", 
            "arm_group_type": "Experimental", 
            "description": "Patients with breast cancer receiving neoadjuvant chemotherapy will undergo quantitative VCEUS imaging and 2D grayscale imaging as follows:\nprior to initiation of treatment (baseline);\nat 14  (\u00b1 4 days) after initiation of neoadjuvant chemotherapy (early treatment);\nat 28 days (\u00b1 4 days) after initiation of neoadjuvant chemotherapy (inter-regimen);\nat completion of therapy prior to definitive surgery (usually 2-3 months after initiation of treatment).  Each patient will undergo a total of four VCEUS examinations."
        }, 
        "brief_summary": {
            "textblock": "1. Evaluate quantitative VCEUS imaging for determining early breast cancer response to\n           neoadjuvant chemotherapy and compare results to co-temporal volume change on grayscale\n           ultrasound and post-treatment mammography findings utilizing final surgical pathology\n           and clinical outcome.\n\n        2. Assess incremental benefit of quantitative VCEUS to planar CEUS tumor perfusion\n           measurements and enhancement patterns in predicting tumor response to adjuvant\n           treatment in clinical studies.\n\n      The contrast agent Definity\u00ae is FDA approved for use as a contrast agent during ultrasound\n      (echocardiography) of the heart.  Definity\u00ae will be used \"off-label\" (during ultrasound of\n      the breast) in this study.  The administration of Definity\u00ae during this study will follow\n      total dose guidelines approved by the FDA."
        }, 
        "brief_title": "Breast VCEUS to Evaluate Early Response to Neoadjuvant Chemotherapy", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult patients (age 19 years or older).\n\n          2. Patients with newly diagnosed and untreated stage II and III breast cancer scheduled\n             to undergo neoadjuvant chemotherapy.\n\n          3. Patients with signed informed consent.\n\n        Exclusion Criteria:\n\n          1. Any history of prior radiation or chemotherapy for breast cancer.\n\n          2. Patients who only have non-measurable disease.\n\n          3. Patients who are medically unstable.\n\n          4. Patients with other primary cancers requiring systemic treatment.\n\n          5. Patients with cardiac shunts.\n\n          6. Patients with unstable cardiopulmonary conditions.\n\n          7. Patients with known pulmonary hypertension.\n\n          8. Patients with known hypersensitivity to any component of Definity (R) microbubble\n             contrast.\n\n          9. Patients who are pregnant, breast-feeding or are planning to become pregnant during\n             the study duration."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01817374", 
            "org_study_id": "R12-021", 
            "secondary_id": "115,576"
        }, 
        "intervention": {
            "arm_group_label": "Definity VCEUS", 
            "description": "This is a pilot study to evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy, comparing results with volume change on grayscale US and planar CEUS, and correlating imaging findings with pathological response on surgical specimens.", 
            "intervention_name": "Definity (Perflutren Lipid Microspheres)", 
            "intervention_type": "Drug", 
            "other_name": [
                "Definity", 
                "Perflutren Lipid Microspheres"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Breast Cancer", 
            "Definity", 
            "Ultrasound"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "contact": {
                "email": "mvetrano@uabmc.edu", 
                "last_name": "Marianne Vetrano, RN", 
                "phone": "205-934-4080"
            }, 
            "facility": {
                "address": {
                    "city": "Birmingham", 
                    "country": "United States", 
                    "state": "Alabama", 
                    "zip": "35294"
                }, 
                "name": "University of Alabama at Birmingham"
            }, 
            "investigator": [
                {
                    "last_name": "Jennifer de los Santos, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Andres Forero, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kenneth Hoyt, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Helen Krontiras, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mark Lockhart, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michelle Robbin, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study Evaluating Quantitative Volume Contrast Enhanced Ultrasound (VCEUS) Imaging for Determining Early Breast Cancer Response to Neoadjuvant Chemotherapy", 
        "overall_contact": {
            "email": "humphrey@uabmc.edu", 
            "last_name": "Heidi R Umphrey, MD", 
            "phone": "(205) 996-4132"
        }, 
        "overall_contact_backup": {
            "email": "mvetrano@uabmc.edu", 
            "last_name": "Marianne Vetrano, RN", 
            "phone": "(205) 934-4080"
        }, 
        "overall_official": {
            "affiliation": "University of Alabama at Birmingham", 
            "last_name": "Heidi R Umphrey, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy and compare results to co-temporal volume change on grayscale US, utilizing final surgical pathology and clinical outcome as reference standards. Specifically, changes in peak signal intensity and area under the curve will be compared with co-temporal changes in volume on grayscale US.", 
            "measure": "VCEUS Quantitative Response vs grayscale US", 
            "safety_issue": "No", 
            "time_frame": "Post neoadjuvant therapy (aproximately 2-3 months after start of treatment)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01817374"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Compare quantitative VCEUS to planar CEUS tumor perfusion measurements and enhancement patterns in predicting tumor response to neoadjuvant treatment utilizing final surgical pathology and clinical outcome as reference standards. Specifically, co-temporal early peak signal intensity and area under the curve will be compared to determine whether increased VCEUS has increased efficacy to determine response to neoadjuvant therapy in breast cancer.  Additionally, pre-surgical imaging will be compared to final surgical pathology,", 
            "measure": "Predicting tumor response", 
            "safety_issue": "No", 
            "time_frame": "Post Neoadjuvant Chemotherapy (aproximately 2-3 months after start of treatment)"
        }, 
        "source": "University of Alabama at Birmingham", 
        "sponsors": {
            "collaborator": {
                "agency": "American Cancer Society, Inc.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Alabama at Birmingham", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}